CA
NVAX icon

Clearstead Advisors’s Novavax NVAX Stock Holding History

Clearstead Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-265
Closed -$56K – 1354
2021
Q2 		$56K Buy
265
+157
+145% +$28.8K ﹤0.01% 536
2021
Q1 		$20K Hold
108
– – ﹤0.01% 681
2020
Q4 		$12K Hold
108
– – ﹤0.01% 697
2020
Q3 		$12K Buy
+108
New +$13.2K ﹤0.01% 645

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clearstead Advisors's NVAX Position: Q3 2021 in Review

Clearstead Advisors sold out of Novavax (NVAX) in Q3 2021, closing a stake of 265 shares — an estimated $56K sold.

Clearstead Advisors first reported a position in NVAX in Q3 2020 and held it in 4 quarters. The position peaked at $56K in Q2 2021. 442 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

  • Clearstead Advisors reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
  • Clearstead Advisors sold 265 Novavax shares in Q3 2021, an estimated $56K.
  • Clearstead Advisors first reported a position in Novavax in Q3 2020 and held it in 4 quarters.
  • Clearstead Advisors's Novavax position peaked at $56K in Q2 2021.
  • 442 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Clearstead Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.